Prevalence, Risk Factors, Treatment and Outcome of multidrug resistance Candida auris Infections in Coronavirus Disease (COVID-19) Patients: A Systematic Review.
Sign Up to like & getrecommendations! Published in 2022 at "Mycoses"
DOI: 10.1111/myc.13447
Abstract: BACKGROUND Candida auris is an emerging multidrug-resistant pathogen in intensive care settings (ICU). During the coronavirus disease 19 (COVID-19) pandemic, ICU admissions were overwhelmed, possibly contributing to the C. auris outbreak in COVID-19 patients. OBJECTIVES… read more here.
Keywords: risk factors; covid patients; prevalence; auris infections ... See more keywords
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
Sign Up to like & getrecommendations! Published in 2020 at "Antibiotics"
DOI: 10.3390/antibiotics9090539
Abstract: Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment.… read more here.
Keywords: triterpenoid antifungal; auris infections; treatment; candida ... See more keywords
Echinocandins as Biotechnological Tools for Treating Candida auris Infections
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Fungi"
DOI: 10.3390/jof6030185
Abstract: Candida auris has been reported in the past few years as an invasive fungal pathogen of high interest. Its recent emergence in healthcare-associated infections triggered the efforts of researchers worldwide, seeking additional alternatives to the… read more here.
Keywords: tools treating; auris infections; echinocandins biotechnological; biotechnological tools ... See more keywords